Promoted Content

Promoted Content

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Chordia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Chordia and Ono Pharmaceutical Enter into Exclusive License Agreement on CTX-177, a MALT1 Inhibitor, and Other Related Compounds

Contact the Supplier

Lead Product(s): CTX-177

Therapeutic Area: Oncology Product Name: CTX-177

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Ono Pharmaceutical

Deal Size: $509.7 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 15, 2020

Details:

Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally.